VASOACTIVE INTESTINAL PEPTIDE (VIP) AS AN OVARIAN PROTECTOR: PREVENTION AGAINST PREMATURE OVARIAN FAILURE DURING CHEMOTHERAPY

OUBIÑA, GONZALO; CLAUDIA PEREZ LEIROS; YAMILA HERRERO; NATALIA PASCUALI; ABRAMOVICH DALHIA; SCOTTI LEOPOLDINA; ROSSANA RAMHORST; FERNANDA PARBORELL

Mar del Plata

Congreso; REUNIÓN ANUAL de Sociedades de Biociencia 2019 SAIC . SAFE . SAB . SAP; 2019

SAIC . SAFE . SAB . SAP

The ovary, in addition to its endocrine and intraovarian control, is regulated by direct neural inputs of peptidergic nature. Vasoactive intestinal peptide (VIP) was originally isolated from the small intestine and lung tissues and plays an important role in ovarian function. Previous studies have found VIP immunoreactivity in ovarian follicles. The objective of this study was to determine the effect of VIP on ovarian function in a doxorubicin (DX) induced-Premature Ovarian Failure (POF) murine model.To induce POF, DX 10mg/kg, i.p. was applied in F1 mice (C57XBalbC 8 weeks old) on day 1. Control and DX mice underwent sham surgery and received an intrabursal injection of saline solution on both ovaries, while DX + VIP groups received either 1μl or 10µl VIP 1µM 1 h prior to DX administration. Sacrifices were made at day 15. The ovaries were isolated for histological analysis and protein extraction for Western Blot assays. For all data analysis ANOVA followed by Tukey test were performed. An ovarian morphological analysis showed that DX decreased the % of primary (PriF), preantral (PF) and early antral follicles (EAF), and increased the % of atretic follicles (AtrF) (p